News Sentiment

VVY sentiment intelligence

Vivoryon Therapeutics N.V. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report RSS feed
Weighted score 54 Balanced news tone 4 relevant articles
Exchange AMS Netherlands
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.40 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings

54/100 classification confidence.

Company focus 4

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+27.3% over one week, +21.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Kidney drug developer Vivoryon lines up June 11 Q1 2026 results

Market Reaction

Price moving ahead of tone

54/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Earnings 54/100 classification
One-week reaction 27.3% Price confirming higher
Trend fit Trend inactive 21.7% over four weeks
Fair value -58.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 1
Neutral 3
Negative 0

Relevance

Why the article matched

Direct first
Direct company coverage 4
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 1
Market source 1
The Pharma Letter 1
StockInvest.us 1

Event Lens

What the news is about

Classified themes
Earnings 1
Balance sheet 1
Market update 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-4 of 4
The Pharma Letter Direct company coverage

Vivoryon Therapeutics

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2024 23:52
Source
The Pharma Letter